Calendar Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
980.2 USD +1.06% Intraday chart for Regeneron Pharmaceuticals, Inc. -0.49% +11.60%

Chart calendar Regeneron Pharmaceuticals, Inc.

80bbce2c191.CsrC3Ar365tbx3iQVCte7HF3uAhkVLF0JSyodotML_Y.bqaaln-9k-0vgQz_bF8d2xAv0F5RC_YRFm7NB-EHdcFQj_WJU6PG4hDySA~5b309ed9eb32557487abbf22809f63ac

Upcoming events on Regeneron Pharmaceuticals, Inc.

Today 10:00 am American Society of Clinical Oncology Meeting - Abstract No : 2650
Today 02:30 pm American Society of Clinical Oncology Meeting - Abstract No: TPS9611
2024-06-02 10:00 am American Society of Clinical Oncology Meeting - Abstract No: 6038
2024-06-02 10:00 am American Society of Clinical Oncology Meeting - Abstract No : 6100
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No: 5522
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No: 7076
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No: 7093
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No: TPS5632
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No: 7094
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No: 7560
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No; 7096
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No: 7086
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No: 7561
2024-06-03 10:00 am American Society of Clinical Oncology Meeting - Abstract No: 7099
2024-06-03 12:30 pm American Society of Clinical Oncology Meeting - Abstract No :2503

Past events on Regeneron Pharmaceuticals, Inc.

2024-05-14 09:00 am RBC Capital Markets Global Healthcare Conference
2024-05-11 08:15 am American Society of Gene & Cell Therapy Meeting - Abstract No -353
2024-05-11 08:00 am American Society of Gene & Cell Therapy Meeting - Pressing Challenges in Gene Therapy
2024-05-10 04:15 pm American Society of Gene & Cell Therapy Meeting - Abstract No - 298
2024-05-09 05:15 pm American Society of Gene & Cell Therapy Meeting - Abstract No - 218
2024-05-09 05:15 pm American Society of Gene & Cell Therapy Meeting - Abstract No - 197
2024-05-09 02:45 pm Association for Research in Vision and Ophthalmology Meeting - Abstract No. #B0170
2024-05-09 02:45 pm Association for Research in Vision and Ophthalmology Meeting - Abstract No. #B0148
2024-05-09 02:45 pm Association for Research in Vision and Ophthalmology Meeting - Abstract No. #B0130
2024-05-09 02:45 pm Association for Research in Vision and Ophthalmology Meeting - Abstract No. #B0129
2024-05-09 10:55 am American Society of Gene & Cell Therapy Meeting - Engineering CAR-T Cells with Novel Receptor Archit
2024-05-08 06:45 pm Association for Research in Vision and Ophthalmology Meeting - Abstract No. #4887
2024-05-08 06:15 pm Association for Research in Vision and Ophthalmology Meeting - Abstract No. #4906
2024-05-08 05:15 pm Association for Research in Vision and Ophthalmology Meeting - Abstract No. #4928
2024-05-08 04:15 pm American Society of Gene & Cell Therapy Meeting - Abstract No - 118
2024-05-08 12:00 pm American Society of Gene & Cell Therapy Meeting - Abstract No - 898
2024-05-08 12:00 pm American Society of Gene & Cell Therapy Meeting - Abstract No -897
2024-05-08 12:00 pm American Society of Gene & Cell Therapy Meeting - Abstract No - 899
2024-05-08 12:00 pm American Society of Gene & Cell Therapy Meeting - Abstract No -638
2024-05-08 09:30 am American Society of Gene & Cell Therapy Meeting - Abstract No - 10

Annual results

Fiscal PeriodDecember 2019 2020 2021 2022 2023 2024
Net sales
Million USD
Released
Forecast
Spread
7 863
7 816
0.61%
8 497
8 494
0.04%
16 072
15 679
2.51%
12 173
11 850
2.73%
13 117
12 921
1.52%

13 822

EBITDA
Million USD
Released
Forecast
Spread
3 420
3 610
-5.28%
4 245
4 158
2.09%
9 835
9 709
1.29%
6 060
6 161
-1.63%
5 547
5 452
1.74%

5 532

EBIT
Million USD
Released
Forecast
Spread
2 210
2 285
-3.29%
3 577
3 485
2.64%
8 947
9 034
-0.96%
5 719
5 561
2.84%
5 126
5 082
0.87%

5 087

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
2 429
2 308
5.26%
3 810
3 582
6.39%
9 326
9 442
-1.23%
4 859
4 812
0.97%
4 199
4 276
-1.8%

4 115

Net income
Million USD
Released
Forecast
Spread
2 116
1 998
5.87%
3 513
3 160
11.18%
8 075
8 014
0.77%
4 338
4 166
4.14%
3 954
3 808
3.83%

3 960

EPS
USD
Released
Forecast
Spread
18,5
17,6
4.67%
30,5
28,0
8.96%
72,0
71,1
1.17%
38,2
36,3
5.31%
34,8
33,9
2.62%

33,8

Announcement Date06/02/2005/02/2104/02/2203/02/2302/02/24-

Quarterly results

Fiscal PeriodDecember 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales
Million USD
Released
Forecast
Spread
2 965
2 690
10.22%
2 857
2 797
2.14%
2 936
2 870
2.29%
3 414
3 113
9.7%
3 162
2 998
5.48%
3 158
3 025
4.41%
3 363
3 222
4.36%
3 434
3 287
4.49%
3 145
3 221
-2.35%

3 372


3 553


3 723


3 566


3 617

EBITDA
Million USD
Released
Forecast
Spread
1 558
1 376
13.24%
1 344
1 220
10.17%
1 488
1 344
10.67%
1 637
1 336
22.54%
1 315
1 219
7.84%
1 351
1 175
14.98%
1 488
1 288
15.47%
1 395
1 500
-7.01%
1 142
1 195
-4.43%

1 311


1 495


1 613


1 193


1 285

EBIT
Million USD
Released
Forecast
Spread
1 483
1 273
16.56%
1 285
1 124
14.37%
1 413
1 266
11.62%
1 537
1 344
14.33%
1 215
1 203
1.01%
1 248
1 216
2.63%
1 382
1 272
8.7%
1 282
1 248
2.74%
1 028
1 168
-12.04%

1 208


1 346


1 411


1 311


1 369

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
1 061
1 185
-10.43%
963
1 116
-13.71%
1 510
984
53.36%
1 325
1 154
14.81%
858
1 009
-14.97%
1 083
1 041
4%
1 111
1 154
-3.72%
1 148
1 308
-12.24%
701
1 212
-42.18%

1 111


1 171


1 196


1 233


1 339

Net income
Million USD
Released
Forecast
Spread
974
1 038
-6.2%
852
794
7.38%
1 316
845
55.67%
1 197
1 060
12.94%
818
876
-6.69%
968
885
9.42%
1 008
1 071
-5.9%
1 160
1 025
13.08%
722
886
-18.54%

1 035


1 145


1 169


1 109


1 155

EPS
USD
Released
Forecast
Spread
8,61
8,77
-1.86%
7,47
7,38
1.29%
11,7
7,93
47.05%
10,5
9,23
13.73%
7,17
7,96
-9.92%
8,50
7,93
7.12%
8,89
9,04
-1.62%
10,2
9,21
10.69%
6,27
7,89
-20.52%

8,79


9,64


9,99


9,80


10,2

Announcement Date04/05/2203/08/2203/11/2203/02/2304/05/2303/08/2302/11/2302/02/2402/05/24-----

Net sales - Quarter - Rate of surprise

Quarterly earnings - Rate of surprise

Net sales - Annual - Rate of surprise

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Calendar Regeneron Pharmaceuticals, Inc.